Journal article
A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
Abstract
Purpose: The epidermal growth factor receptor (EGFR) appears relevant in the pathogenesis and progression of colorectal cancer. After completing a phase I pharmacodynamic trial of ZD1839, we undertook a dose expansion trial to examine the antitumour efficacy and adverse effect profile of this agent in a homogeneous group of patients with metastatic colorectal cancer (CRC). Experimental design: Eligible patients with metastatic or recurrent CRC …
Authors
MacKenzie MJ; Hirte HW; Glenwood G; Jean M; Goel R; Major PP; Miller Jr. WH; Panasci L; Lorimer IAJ; Batist G
Journal
Investigational New Drugs, Vol. 23, No. 2, pp. 165–170
Publisher
Springer Nature
Publication Date
January 2005
DOI
10.1007/s10637-005-5862-9
ISSN
0167-6997